Biogen gives up seeking European approval for aducanumab - Drug Discovery and Development
EMA gives thumbs down to Biogen's Alzheimer's drug aducanumab - Drug Discovery and Development
Biogen releases long-term Aduhelm data
EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING
Aduhelm (aducanumab) Q+A - Penn Memory Center
Biogen's Alzheimer's drug approved by FDA, first new therapy in nearly two decades
Press Releases – Page 2 – Global Alzheimer's Platform Foundation
U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients | Reuters
Medicare Finalizes Limits on Aducanumab Coverage | MedPage Today
FDA changes prescribing instructions to limit use of contentious Alzheimer's drug amid public backlash | KTLA
Biogen is ready to roll on lecanemab production, CFO says
Biogen's Aducanumab: A Look at the Drug's History and Recent Updates | BioSpace
James Deardorff on X: ""Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease" - Hmm... 1. https://t.co/k7Ga4ja0br 2. https://t.co/5cr8gYW72s https://t.co/7NboyUVjWr" / X
/cloudfront-us-east-2.images.arcpublishing.com/reuters/YOZVWDX35VKEVCOQV4LDNO3ZTQ.jpg "U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day\" for patients | Reuters")
U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients | Reuters
Early Access Programs | Biogen
Aducanumab: New Medication FDA Approved for Alzheimer's Disease – Psychiatry Education Forum
Aduhelm safety: the data gap on aducanumab's brain swelling side effect
Biogen stuns with planned US FDA filing for previously scrapped Alzheimer's drug | S&P Global Market Intelligence
Biogen readies Alzheimer's hopeful aducanumab for U.S. launch as stateside sales plummet | Fierce Pharma
FDA approves much-debated Alzheimer's drug panned by experts | AP News
FDA Approval of a New Alzheimer's Drug Comes With Controversy | Smart News| Smithsonian Magazine
FDA approves much-debated Alzheimer's drug panned by experts | AP News
Controversial FDA Approval Of Alzheimer's Drug Aducanumab Sets Stage For Possible Medicare Coverage Battle
Congressional Investigation into Alzheimer's Drug Aduhelm Faults the F.D.A. and Biogen - The New York Times
Aducanumab: will Biogen's Aduhelm recover from its rocky start? - Pharmaceutical Technology
Congressional Probe of Alzheimer's Drug Approval Finds Fault With FDA Actions | MedPage Today
Biogen Reverses Take on Aducanumab Trial Data | MedPage Today
